Post by JHam on Jul 13, 2014 16:32:45 GMT
There is no mention of ONCS in this article from July 1st, 2014, so maybe I should mark it as off-topic. However, I thought this clip was interesting in how it could relate to ONCS.
Pembrolizumab is currently under review in the U.S. as well where a response from the FDA should be out by Oct 28. Pembrolizumab has Breakthrough Therapy designation for advanced melanoma in the U.S. and FDA approval this October would make it the first anti-PD-1 therapy to be approved in the country. Merck is evaluating pembrolizumab for more than 30 types of cancer alone and in combination with other therapies.
www.zacks.com/stock/news/138678/Will-Mercks-AntiPD1-Therapy-be-the-First-to-Launch
I could be totally wrong in my assessment with all of this. Just trying to do some dot-connecting. Given ONCS' strong connections with Merck it just makes logical sense in my opinion.
Pembrolizumab is currently under review in the U.S. as well where a response from the FDA should be out by Oct 28. Pembrolizumab has Breakthrough Therapy designation for advanced melanoma in the U.S. and FDA approval this October would make it the first anti-PD-1 therapy to be approved in the country. Merck is evaluating pembrolizumab for more than 30 types of cancer alone and in combination with other therapies.
www.zacks.com/stock/news/138678/Will-Mercks-AntiPD1-Therapy-be-the-First-to-Launch
I could be totally wrong in my assessment with all of this. Just trying to do some dot-connecting. Given ONCS' strong connections with Merck it just makes logical sense in my opinion.